SMRT Antibody [M7D13] | Primary Antibodies

Application: Reactivity: Human, Monkey

Lane 1: MOLT-4

Usage Information

Dilution
WB1:1000 CHIP1:50

Application
WB, ChIP

Reactivity
Human, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
270 kDa

Datasheet & SDS

Biological Description

Specificity
SMRT Antibody [M7D13] detects endogenous levels of total SMRT protein.

Clone
M7D13

Synonym(s)
Silencing mediator of retinoic acid and thyroid hormone receptor; SMRT; NCOR2

Background
SMRT belongs to the NCoR/SMRT family of nuclear receptor corepressors that mediate transcriptional silencing by assembling multi-subunit repressive complexes on unliganded nuclear receptors. SMRT organizes N-terminal repression domains interspersed with SANT motifs alongside C-terminal CoRNR box interaction domains that form amphipathic helices docking into hydrophobic grooves on receptor ligand-binding domains. SMRT bridges nuclear receptors to HDAC3 through a deacetylase activation domain encompassing the first SANT motif that allosterically relieves HDAC3 autoinhibition by stabilizing its catalytic pocket, while the second SANT motif forms a histone interaction domain that preferentially binds unacetylated H3/H4 tails to enhance substrate presentation and amplify deacetylation at target promoters. Repression domains recruit mSin3A, GPS2, and TBL1/TBLR1 scaffolds that propagate silencing through coordinated histone hypoacetylation, DNA methylation, and chromatin compaction via recruitment of HP1 and PRC2 complexes. Interaction with thyroid hormone and retinoic acid receptors enforces lineage-specific gene repression during development, with alternative splicing generating isoforms that modulate receptor specificity through variable usage of the CoRNR box. SMRT governs metabolic homeostasis by silencing lipogenic programs in liver and adipogenesis in mesenchymal precursors, with dynamic exchange dictated by ligand-induced conformational shifts that evict corepressor for coactivator binding. Dysregulation through translocation or mutation impairs hormone responsiveness in acute promyelocytic leukemia and thyroid disorders.

Background

SMRT belongs to the NCoR/SMRT family of nuclear receptor corepressors that mediate transcriptional silencing by assembling multi-subunit repressive complexes on unliganded nuclear receptors. SMRT organizes N-terminal repression domains interspersed with SANT motifs alongside C-terminal CoRNR box interaction domains that form amphipathic helices docking into hydrophobic grooves on receptor ligand-binding domains. SMRT bridges nuclear receptors to HDAC3 through a deacetylase activation domain encompassing the first SANT motif that allosterically relieves HDAC3 autoinhibition by stabilizing its catalytic pocket, while the second SANT motif forms a histone interaction domain that preferentially binds unacetylated H3/H4 tails to enhance substrate presentation and amplify deacetylation at target promoters. Repression domains recruit mSin3A, GPS2, and TBL1/TBLR1 scaffolds that propagate silencing through coordinated histone hypoacetylation, DNA methylation, and chromatin compaction via recruitment of HP1 and PRC2 complexes. Interaction with thyroid hormone and retinoic acid receptors enforces lineage-specific gene repression during development, with alternative splicing generating isoforms that modulate receptor specificity through variable usage of the CoRNR box. SMRT governs metabolic homeostasis by silencing lipogenic programs in liver and adipogenesis in mesenchymal precursors, with dynamic exchange dictated by ligand-induced conformational shifts that evict corepressor for coactivator binding. Dysregulation through translocation or mutation impairs hormone responsiveness in acute promyelocytic leukemia and thyroid disorders.

References
https://pubmed.ncbi.nlm.nih.gov/12840002/ https://pubmed.ncbi.nlm.nih.gov/9415406/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%